RHHBY

Healthcare

Roche Holding AG · Drug Manufacturers - General · $321B

UQS Score — Balanced Preset
63.1
Good

Roche Holding AG scores 63.1/100 using the Balanced preset.

90.0
Quality
35%
50.0
Moat
30%
41.9
Growth
20%
57.1
Risk
15%

RHHBY — Key Takeaways

✅ Strengths

Roche Holding AG shows strong profitability and capital efficiency
Roche Holding AG shows attractive valuation relative to fundamentals

RHHBY — Score History

55606570Apr 5Apr 6Apr 7Apr 8
DateUQSQualityMoatGrowthRiskValueChange
Apr 8, 202663.190.050.041.957.174.30.0
Apr 7, 202663.190.050.041.957.174.30.0
Apr 6, 202663.190.050.041.957.174.30.0
Apr 5, 202663.190.050.041.957.174.3

RHHBY — Pillar Breakdown

Quality

90.0/100 (25%)

Roche Holding AG demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.

Capital Efficiency (ROIC)Strong

How effectively capital is deployed to generate returns.

Return on EquityStrong

Profitability relative to shareholders' equity.

Operating ProfitabilityStrong

Ability to convert revenue into operating profit.

Net ProfitabilityStrong

Bottom-line profit as a share of revenue.

Gross Profit / AssetsStrong

Asset productivity — how much gross profit each dollar of assets generates.

Cash GenerationModerate

Free cash flow relative to market value.

Growth

41.9/100 (20%)

Roche Holding AG shows steady but unspectacular growth, typical for mature companies.

Recent Revenue TrendWeak

Revenue trajectory over the last twelve months.

3Y Revenue CAGRWeak

Compound annual revenue growth rate over 3 years.

EPS GrowthStrong

Year-over-year earnings per share growth.

Forward Revenue OutlookWeak

Analyst consensus for future revenue growth.

Forward EPS GrowthStrong

Analyst consensus for future earnings growth.

Risk

57.1/100 (15%)

Roche Holding AG maintains a reasonable risk profile with manageable debt levels.

Financial LeverageModerate

Debt levels relative to earnings capacity.

Debt/EquityModerate

Total debt relative to shareholder equity.

Current RatioWeak

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageStrong

Earnings capacity relative to interest payments.

Valuation

74.3/100 (15%)

Roche Holding AG trades at a reasonable valuation with decent earnings yield and FCF multiples.

Earnings YieldModerate

Inverse of forward P/E — higher yield means cheaper stock.

Price to Free Cash FlowStrong

How many years of FCF the market cap represents.

PEG RatioStrong

P/E relative to earnings growth — lower is more attractive.

Moat

50/100 (30%)

Roche Holding AG possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RHHBY.

Score Composition

Quality
90.0×25%22.5
Growth
41.9×20%8.4
Risk
57.1×15%8.6
Valuation
74.3×15%11.1
Moat
50.0×30%15.0
Total
63.1Good

Unlock Full RHHBY Analysis

Sign in to access detailed financial metrics, interactive price charts, custom pillar weights, 6 investor presets, and watchlist tracking.

✓ Detailed ratios✓ Price chart✓ Custom moat ratings✓ 6 investor presets✓ Watchlist
Analyze RHHBY in Detail →

More Stock Analysis

How is the RHHBY UQS Score Calculated?

The UQS (Unified Quality Score) for Roche Holding AG is calculated using a proprietary 5-pillar framework with 25 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Roche Holding AG's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Roche Holding AG is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.